Phase II Study of Taxotere in Combination With Exisulind in Non-Small Cell Lung Cancer (NSCLC) Patients - Contacts and Locations

Home

Phase II Study of Taxotere in Combination With Exisulind in Non-Small Cell Lung Cancer (NSCLC) Patients

This study has been completed.

Study NCT00072618. Last updated on October 10, 2006. Information provided by OSI Pharmaceuticals

Please refer to this study by its ClinicalTrials.gov identifier: NCT00072618

Locations


United States, Colorado
	University of Colorado Health Sciences Center
	Aurora, Colorado, United States, 80045

United States, Illinois
	University of Chicago Medical Center
	Chicago, Illinois, United States, 60637

Sponsors and Collaborators

OSI Pharmaceuticals